NPPA clarifies annual price hike eligibility for anti-cancer drugs under trade margin rationalisation

The National Pharmaceutical Pricing Authority (NPPA) has clarified that manufacturers of anti-cancer drugs covered by trade margin rationalisation can avail annual price increases under Paragraph 20(1) of DPCO, 2013, from implementation of revised MRP by November 9, 2026, or 12 months after the last MRP revision if unchanged. The clarification provides manufacturers with greater certainty on price revision timelines following trade margin rationalisation.

Join our 1500+ subscribers to get our daily Health Laws and Policy Updates.